A new blood-test approach could help scientists identify early immune changes linked to Crohn’s disease and ulcerative colitis long before symptoms appear.
What if a serious intestinal disease could be detected in your blood years before you experienced the first warning sign?
That possibility is moving closer to scientific investigation after researchers identified distinctive patterns of antibodies associated with inflammatory bowel disease (IBD) in blood samples collected long before patients received a diagnosis.
The study, reported by The Guardian on October 18, 2026, examined blood samples from 500 US military personnel. Researchers found that certain immune-system changes were associated with the later development of Crohn’s disease and ulcerative colitis, sometimes appearing as much as a decade before diagnosis.
The findings could eventually help doctors recognize people at increased risk earlier, potentially creating opportunities to investigate the disease before substantial intestinal damage develops. However, the approach remains experimental and is not yet a routine screening test.
What Did Scientists Discover?
Researchers analyzed approximately 2,000 blood samples collected from 500 individuals, including people who later developed inflammatory bowel disease and others who did not.
The team examined antibodies produced by the immune system in response to a wide range of protein fragments associated with microbes, viruses, food and the body’s own tissues.
Antibodies are proteins that help the immune system recognize particular targets. Their presence can provide clues about how the immune system has responded to exposures or changes inside the body.
The researchers found that people who subsequently developed IBD displayed distinct antibody patterns years before their conditions were diagnosed.
Importantly, the patterns differed between the two major forms of the disease. This suggests that Crohn’s disease and ulcerative colitis may involve different immune-system changes during their early development.
The findings were presented at the United European Gastroenterology meeting in Barcelona and reported in The Guardian. The research offers a potential route toward earlier detection, although further studies will be needed to establish how accurately the approach can predict disease in the general population.
Crohn’s Disease and Ulcerative Colitis: Two Different Conditions
Inflammatory bowel disease is not a single illness. It primarily includes Crohn’s disease and ulcerative colitis, chronic conditions involving inflammation of the digestive tract.
Crohn’s disease can affect any part of the gastrointestinal tract, from the mouth to the anus. Inflammation may extend through multiple layers of the intestinal wall and can lead to complications such as narrowing of the bowel, abscesses or abnormal connections called fistulas.
Ulcerative colitis primarily affects the large intestine and rectum. It causes inflammation and ulcers in the lining of the colon and can lead to persistent diarrhea, abdominal pain and rectal bleeding.
Both conditions can significantly affect a person’s quality of life. Their symptoms may fluctuate, with periods of relative improvement followed by episodes of active disease.
Diagnosis can also be challenging because early symptoms may resemble those of other digestive conditions. Some patients experience delays before receiving an accurate diagnosis.
Detecting biological changes before symptoms emerge could eventually help doctors identify individuals who warrant closer assessment.
The Epstein-Barr Virus Connection
One particularly interesting finding involved the Epstein-Barr virus, a widespread virus best known for causing infectious mononucleosis, sometimes called glandular fever.
Researchers found that people who later developed Crohn’s disease were more likely to show particular antibody responses against the virus. These differences were detectable years before diagnosis and appeared strongest among some individuals who subsequently developed more severe disease.
The finding raises questions about the relationship between viral exposure, immune-system activity and the development of intestinal inflammation.
However, it does not prove that Epstein-Barr virus causes Crohn’s disease. The virus infects a large proportion of the world’s population, while only a small proportion of people develop Crohn’s disease.
The antibody pattern may represent one piece of a much more complicated biological process involving genetics, environmental factors, the gut microbiome and immune regulation.
People should not interpret evidence of Epstein-Barr virus exposure as an indication that they will develop inflammatory bowel disease.
Why Ulcerative Colitis Showed a Different Pattern
The researchers also identified a distinct immune signature among people who later developed ulcerative colitis.
Some of these individuals displayed antibodies directed against proteins belonging to their own bodies. Such responses are sometimes described as autoreactive because the immune system recognizes components of the body’s own tissues.
This finding may help scientists investigate how immune-system abnormalities develop before ulcerative colitis becomes clinically apparent.
Nevertheless, the presence of an antibody targeting a human protein does not automatically establish that a person has an autoimmune disease or will develop one.
The researchers must determine which antibody patterns are sufficiently specific and reliable to distinguish people who will develop IBD from those who will remain healthy.
Could a Blood Test Prevent Intestinal Damage?
The greatest potential benefit would be identifying people at risk before they develop persistent symptoms or significant complications.
Today, diagnosing IBD generally involves assessing symptoms, blood and stool tests, endoscopy, imaging and, when appropriate, tissue biopsies. No single antibody test can currently predict every future case of Crohn’s disease or ulcerative colitis.
If future research validates the newly identified patterns, doctors might eventually use them alongside other clinical information to determine who could benefit from additional monitoring.
That could be particularly important if scientists develop safe treatments capable of delaying disease onset or reducing the risk of complications in people identified during an early biological phase.
However, identifying risk is not the same as preventing disease. Researchers still need to demonstrate that testing improves clinical decisions and that any resulting intervention produces meaningful benefits.
What Happens Next?
The findings require validation in independent and more diverse populations. The original study involved US military personnel, so its results may not translate directly to everyone, including children, older adults and populations with different genetic backgrounds or environmental exposures.
Researchers must also determine how often the proposed antibody patterns produce false alarms, how many future cases they miss and whether they can predict when disease will develop.
Until those questions are answered, the method should be regarded as a research tool rather than a test people should seek out for routine screening.
Anyone experiencing persistent diarrhea, unexplained weight loss, ongoing abdominal pain or blood in their stool should seek medical assessment rather than wait for a future predictive test.
The discovery offers a promising new way to investigate how inflammatory bowel disease develops. It suggests that the immune system may leave measurable clues long before Crohn’s disease or ulcerative colitis becomes apparent.
For now, scientists have identified an important possibility, not a guaranteed early-warning system. But if subsequent research confirms the results, a future blood test could help medicine move toward recognizing these serious intestinal diseases earlier—and understanding them before symptoms take over a person’s life.
Medical disclaimer: This article is for informational purposes only and does not replace professional medical advice, diagnosis or treatment.
